AI model for accelerating
translational medicine
and drug discovery
translational medicine
and drug discovery
AI model for
accelerating translational medicine
and drug discovery
accelerating translational medicine
and drug discovery
Previous slide
Next slide

PARTNERING - COLLABORATION MAKES US BETTER!
By harnessing an AI model, AgnistaBio enables its partners to swiftly
(1) design highly developable human antibody against any target protein of interest, including their cryptic epitopes or multiprotein complex specific epitopes;
(2)identify novel interacting/regulating proteins/enzymes against target protein of interest and its detail 4D structures for accelerating drug design on a proteome scale in short lead time.
AgnistaBio is seeking pharma/biotech companies to license or co-develop its potential therapeutic candidates.
Drug Development
AgnistaAI accelerates the discovery of novel therapeutic antibodies and uncovers its unexpected interacting proteins to avoid potential side effects in clinics.